Recommendations on the certification of reference standards for structure identification of recombinant therapeutic proteins

Author:

Ustinnikova O. B.1ORCID,Volkova R. A.1ORCID,Movsesyants A. A.1ORCID,Merkulov V. A.2ORCID,Bondarev V. P.1ORCID

Affiliation:

1. Scientific Centre for Expert Evaluation of Medicinal Products

2. Scientific Centre for Expert Evaluation of Medicinal Products; I. M. Sechenov First Moscow State Medical University (Sechenov University)

Abstract

Reference standards for structure identification of recombinant therapeutic proteins are essential for quality assessment of recombinant protein-based biotechnological medicinal products. The development and certification of such reference standards hold special relevance because of, firstly, the absence of international, national or compendial reference standards for a number of new or recently approved proteins and, secondly, the disruption of supply chains providing the biopharmaceutical industry of the Russian Federation with international reference standards. Moreover, international and national regulatory documents contain only general requirements for the procedure of reference standards certification but not the considerations specific to the standards for biotechnologicals’ structure identification, which vary with the production technologies for each individual active moiety. The aim of this work was to provide recommendations on the procedure for the development and certification of reference standards used to identify the structure of recombinant therapeutic proteins. These recommendations define 4 main stages of the procedure: stage 1 covers the development of requirements for the reference standard, including the justification of material and formulation choices, the elaboration of quality specifications, and the assessment of quality; stage 2 comprises the selection of analytical procedures and the establishment of the values for the certified parameters; stage 3 includes stability studies and shelf-life setting; and stage 4 involves the development of documentation for the reference standard. The paper dwells upon the scope of the stages, taking into account the specific considerations for recombinant therapeutic proteins and the use of reference standards. The recommendations are based upon the extensive experience in biotechnologicals testing and standardisation of the employees of the Scientific Centre for Expert Evaluation of Medicinal Products. These recommendations can provide a base for the establishment of protein-specific certification programmes for reference standards used in structure identification. This approach will allow for systematisation of the process for standards development and ensure the traceability of information and the validity of results. The reference standards certified in accordance with these recommendations can be considered primary standards, if necessary.

Publisher

SCEEMP

Subject

General Earth and Planetary Sciences,General Environmental Science

Reference8 articles.

1. Bondarev VP, Borisevich IV, Volkova RA, Fadeykina OV. Industry reference standards certification for the control of medical immunobiological preparation. Vedomosti nauchnogo centra ekspertizy sredstv medicinskogo primeneniya = Scientific Center for Expartise of Medical Application Products Bulletin. 2013;(2):28–32 (In Russ.)

2. Volkova RA, Fadeikina OV, Klimov VI, Sakanyan EI, OlefirYuV, Merkulov VA, et al. Topical issues related to reference standards in the sphere of circulation of biological products. Biopreparaty. Profilaktika, diagnostika, lechenie = BIOpreparation. Prevention, Diagnosis, Treatment. 2016;16(4):229–36 (In Russ.)

3. Fadeikina OV, Volkova RA. Elaboration of certification procedures for reference standards of biological drugs. Khimiko-farmatsevtichesrii zhurnal = Pharmaceutical Chemistry Journal. 2017;51(8):44–50 (In Russ.) http://doi.org/10.30906/0023-1134-2017-51-8-44-50.

4. Volkova RA, Fadeikina OV, Ustinnikova OB, Sakanyan EI, Merkulov VA, Movsesyants AA, et al. Current problems with the standard samples of medicines in the Russian Federation. Farmaciya = Pharmacy. 2020;69(2):5–11 (In Russ.) https://doi.org/10.29296/25419218-2020-02-01

5. Goloshchapova EO, Runova OB, Ustinnikova OB. Recombinant human interferons beta-1a and beta-1b: protein structural features and problematic issues of identity confirmation. Khimiko-farmatsevtichesrii zhurnal = Pharmaceutical Chemistry Journal. 2018;52(8):61–4 (In Russ.) http://doi.org/10.30906/0023-1134-2018-52-8-61-64

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Requirements for the information on reference standards submitted in the dossier for biologicals;Biological Products. Prevention, Diagnosis, Treatment;2024-03-01

2. Development and validation of a peptide-mapping procedure for a novel C1 esterase inhibitor;Biological Products. Prevention, Diagnosis, Treatment;2023-06-05

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3